$0.85
0.12% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US50107A1043
Symbol
KRON
Sector
Industry

Kronos Bio Inc Stock price

$0.85
-0.11 11.46% 1M
-0.13 13.39% 6M
-0.40 32.00% YTD
-0.06 6.59% 1Y
-15.90 94.93% 3Y
-18.15 95.53% 5Y
-18.15 95.53% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.00 0.12%
ISIN
US50107A1043
Symbol
KRON
Sector
Industry

Key metrics

Market capitalization $51.25m
Enterprise Value $-47.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.62
EV/Sales (TTM) EV/Sales -4.85
P/S ratio (TTM) P/S ratio 5.20
P/B ratio (TTM) P/B ratio 0.46
Revenue growth (TTM) Revenue growth 146.48%
Revenue (TTM) Revenue $9.86m
EBIT (operating result TTM) EBIT $-79.71m
Free Cash Flow (TTM) Free Cash Flow $-77.66m
Cash position $124.86m
EPS (TTM) EPS $-1.44
P/E forward negative
P/S forward 5.48
EV/Sales forward negative
Short interest 1.15%
Show more

Is Kronos Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Kronos Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Kronos Bio Inc forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Kronos Bio Inc forecast:

Buy
33%
Hold
67%

Financial data from Kronos Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
9.86 9.86
147% 147%
100%
- Direct Costs 1.79 1.79
55% 55%
18%
8.08 8.08
40,300% 40,300%
82%
- Selling and Administrative Expenses 29 29
17% 17%
292%
- Research and Development Expense 57 57
34% 34%
580%
-78 -78
36% 36%
-790%
- Depreciation and Amortization 1.79 1.79
55% 55%
18%
EBIT (Operating Income) EBIT -80 -80
36% 36%
-808%
Net Profit -86 -86
28% 28%
-868%

In millions USD.

Don't miss a Thing! We will send you all news about Kronos Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kronos Bio Inc Stock News

Neutral
GlobeNewsWire
one day ago
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –
Neutral
GlobeNewsWire
24 days ago
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –
Neutral
GlobeNewsWire
about one month ago
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects –
More Kronos Bio Inc News

Company Profile

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, which engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic transcription factors, small cell, prostate cancer, and MYC-driven cancers. The company was founded by Angela Koehler and Joshua Kazam in 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Norbert Bischofberger
Employees 63
Founded 2017
Website www.kronosbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today